{"entity":{"id":"nct07070349","kind":"trial","name":"A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of HRS-6213 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","summary":"A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07070349 by Jiangsu HengRui Medicine Co., Ltd., with 48 participants planned, started 2025-07-10 and due to reach its primary completion in 2026-01. Interventions recorded: HRS-6213.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07070349","url":"https://clinicaltrials.gov/study/NCT07070349"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07070349","phase":"1/2","setting":"A Phase I/II Clinical Study to Evaluate the Safety, Radiation Dosimetry, Pharmacokinetics, and Preliminary Diagnostic Efficacy of HRS-6213 in Healthy Subjects and Patients With Solid Tumors","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","enrolled":48,"outcomes":[]},"route":"/trials/nct07070349/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}